India’s NPPA To Conduct National Drug Maker Survey
This article was originally published in PharmAsia News
India's National Pharmaceutical Pricing Authority plans to conduct a national census on drug makers in the country. The NPPA expects the survey to provide the basis for future policy and planning of pharmaceutical matters. The survey is intended to cover investments, pricing, product specifications and good manufacturing practices. NPPA's chairman said more than 10,000 drug manufacturing units would be contacted for the survey. (Click here for more
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.